Axcella Announces Upcoming Investor Conference Presentation

Rhea-AI Summary

Axcella (NASDAQ: AXLA) will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021. The live audio webcast of the presentation is scheduled for 4:30 p.m. ET and can be accessed via the company's website. A replay will be available for 90 days. Axcella is focused on treating complex diseases through its proprietary endogenous metabolic modulator (EMM) compositions. Its lead candidates are in Phase 2/2b development targeting overt hepatic encephalopathy (OHE) and non-alcoholic steatohepatitis (NASH).

H.C. Wainwright 5th Annual NASH Investor Conference fireside chat and webcast to be available on October 12

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced that management will be presenting at the H.C. Wainwright 5th Annual NASH Investor Conference.

A live audio webcast of this discussion will be available on the “Investors & News” section of the company’s website, www.axcellahealth.com, at 4:30 p.m. ET on October 12, 2021. A replay will also be available on Axcella’s website for 90 days following the presentation.

Internet Posting of Information

Axcella uses its website, www.axcellahealth.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the company’s website in the “Investors & News” section. Accordingly, investors should monitor this portion of the company’s website, in addition to its press releases, SEC filings and public conference calls and webcasts.

About Axcella

Axcella is a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions. The company’s product candidates are comprised of EMMs and their derivatives that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. Axcella’s pipeline includes lead therapeutic candidates in Phase 2/2b development for the reduction in risk of overt hepatic encephalopathy (OHE) recurrence and the treatment of non-alcoholic steatohepatitis (NASH). For more information, please visit www.axcellahealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005084/en/

Company Contact

Jason Fredette

jfredette@axcellahealth.com

857.320.2236

 

Source: Axcella

FAQ

What is Axcella presenting at the NASH Investor Conference on October 12, 2021?

Axcella will present its innovative approaches to treating complex diseases at the H.C. Wainwright 5th Annual NASH Investor Conference.

When can I listen to Axcella's presentation at the NASH Investor Conference?

The live audio webcast of Axcella's presentation will be available at 4:30 p.m. ET on October 12, 2021.

How long will the replay of Axcella's conference presentation be available?

A replay of Axcella's presentation will be available on their website for 90 days following the event.

What are the key areas Axcella is focusing on for its treatments?

Axcella is developing therapies targeting overt hepatic encephalopathy and non-alcoholic steatohepatitis using endogenous metabolic modulator compositions.

How does Axcella communicate its important news to investors?

Axcella uses its website to disclose material nonpublic information and complies with Regulation FD through its Investors & News section.